Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Negroski, Sutherland & Hanes Neurology
mi
from
Sarasota, FL
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Negroski, Sutherland & Hanes Neurology
mi
from
Sarasota, FL
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Columbus Research & Wellness Institute
mi
from
Columbus, GA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Columbus Research & Wellness Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Neurology of Central Georgia
mi
from
Macon, GA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Neurology of Central Georgia
mi
from
Macon, GA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research, LLC
mi
from
Savannah, GA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research, LLC
mi
from
Savannah, GA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
College Park Family Care Center
mi
from
Overland Park, KA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
College Park Family Care Center
mi
from
Overland Park, KA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
University System of Maryland
mi
from
Baltimore, MD
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
University System of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
International Neurorehabilitation Institute
mi
from
Lutherville, MD
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
International Neurorehabilitation Institute
mi
from
Lutherville, MD
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Milford Regional Medical Center
mi
from
Hopedale, MA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Milford Regional Medical Center
mi
from
Hopedale, MA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
CentraState Medical Center
mi
from
Freehold, NJ
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
CentraState Medical Center
mi
from
Freehold, NJ
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
NYU Langone
mi
from
Brooklyn, NY
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
NYU Langone
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Strotira, Inc.
mi
from
New York, NY
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Strotira, Inc.
mi
from
New York, NY
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Alpha Neurology
mi
from
Staten Island, NY
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Alpha Neurology
mi
from
Staten Island, NY
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Five Towns Neurology
mi
from
Woodmere, NY
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Five Towns Neurology
mi
from
Woodmere, NY
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Braunstein Neurology
mi
from
Mooresville, NC
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Braunstein Neurology
mi
from
Mooresville, NC
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Dayton Center for Neurological Disorders
mi
from
Centerville, OH
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Dayton Center for Neurological Disorders
mi
from
Centerville, OH
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic Inc.
mi
from
Toledo, OH
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic Inc.
mi
from
Toledo, OH
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Oak Clinic for Multiple Sclerosis
mi
from
Uniontown, OH
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Oak Clinic for Multiple Sclerosis
mi
from
Uniontown, OH
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Optimum Neurology
mi
from
Bala-Cynwyd, PA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Optimum Neurology
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Irene Greenhouse MD
mi
from
Jamison, PA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Irene Greenhouse MD
mi
from
Jamison, PA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Neurology and Stroke Associates
mi
from
Lititz, PA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Neurology and Stroke Associates
mi
from
Lititz, PA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
D. Gary Kolva, MD, Neurology
mi
from
West Reading, PA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
D. Gary Kolva, MD, Neurology
mi
from
West Reading, PA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Colonial Healthcare
mi
from
Sumter, SC
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Colonial Healthcare
mi
from
Sumter, SC
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Ogden Clinic
mi
from
Ogden, UT
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Ogden Clinic
mi
from
Ogden, UT
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Dominion Neurological Services
mi
from
Richmond, VA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Dominion Neurological Services
mi
from
Richmond, VA
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
MedStar Health
mi
from
Washington,
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
MedStar Health
mi
from
Washington,
Click here to add this to my saved trials
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated:  12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
Status: Enrolling
Updated: 12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
NoesisPharma
mi
from
Phoenix, AZ
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
NoesisPharma
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
NRC Research Institute
mi
from
Orange, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
VA San Diego Healthcare System
mi
from
San Diego, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
New Foundation Medical Group Clinical Trials
mi
from
Tustin, CA
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
New Foundation Medical Group Clinical Trials
mi
from
Tustin, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Lytle and Weiss, PLLC dba Clinical Trials of the Rockies
mi
from
Denver, CO
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Lytle and Weiss, PLLC dba Clinical Trials of the Rockies
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Connecticut Clinical Research
mi
from
Cromwell, CT
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Connecticut Clinical Research
mi
from
Cromwell, CT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Coastal Connecticut Research, LLC
mi
from
New London, CT
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Coastal Connecticut Research, LLC
mi
from
New London, CT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Neurology Offices of South Florida
mi
from
Boca Raton, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Neurology Offices of South Florida
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Quantum Laboratories
mi
from
Deerfield Beach, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Quantum Laboratories
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Direct Helpers Research Center
mi
from
Hialeah, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Direct Helpers Research Center
mi
from
Hialeah, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Berma Research Group
mi
from
Hialeah, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Berma Research Group
mi
from
Hialeah, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Global Medical Institutes, LLC
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Global Medical Institutes, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Innova Clinical Trials
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Innova Clinical Trials
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Advance Medical Research Center
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Advance Medical Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  12/31/1969
United Health Research Corp.
mi
from
Miami, FL
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 12/31/1969
United Health Research Corp.
mi
from
Miami, FL
Click here to add this to my saved trials